BCG Vaccine Shows Potential in Reducing Dementia Risk, Johns Hopkins Study Finds

Researchers at Johns Hopkins Medicine report that the BCG vaccine, long used against tuberculosis and bladder cancer, may limit Alzheimer's-related protein accumulation, reduce brain inflammation, and improve memory in preclinical models. The findings are preliminary and based on animal or early-stage research, with human efficacy unproven. If validated, this could repurpose an existing, inexpensive vaccine for dementia prevention, a major public health opportunity.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works